Sasha Jovanovic
3 min read
Almirall has delivered a 39.6% gain over the past three years, which puts fresh attention on a simple question for anyone looking at the stock today. Is the current share price adequately backed by the cash flows the business is expected to generate?
-
A 39.6% return over three years means long term holders have seen meaningful value created on paper. That raises the issue of how much of that performance is already reflected in the price.
-
The group’s focus on prescription dermatology and its need to keep investing in research, product launches and commercial reach can affect how much free cash actually makes its way back to shareholders and when it arrives.
-
What if you looked at Almirall through its earnings instead? See why Almirall’s 41.3x P/E tells a different valuation story.
The issue now is whether the cash flows implied by Almirall’s current share price look well supported by the business it runs today and the investments it needs to keep making.
If you want to test the same cash flow question beyond Almirall, you can compare it across a wider field using 225 high quality undervalued stocks.
Does Almirall Look Undervalued on Cash Flow?
The Discounted Cash Flow model here takes Almirall’s future free cash generation and brings it back to today’s money. Over the last twelve months the group produced free cash flow of about €64.9 million, and the projections used in the model assume this pool of cash grows over time rather than shrinks.
What really matters for you as a shareholder is how that stream compares with the current share price of €11.22. The cash flow path baked into this DCF points to a recovering and then growing profile for Almirall, which supports an estimated intrinsic worth that the model describes as substantially above where the stock trades today. That gap reflects expectations that the prescription dermatology pipeline and ongoing investment eventually convert into higher free cash flow than the market is pricing in at the moment. Find out what Almirall could be worth using our Discounted Cash Flow (DCF) estimate.
The Almirall Narrative: What Would Justify Today’s Price?
Narratives pick up where that valuation puzzle leaves off for Almirall. They spell out which paths for growth, profitability and earnings would need to hold for the stock to trade materially higher or lower than today’s level, and each scenario ties a fair value to a specific mix of potential catalysts and risks so you can track over time which version of Almirall’s story appears to be taking shape on the Community page.
